Skp2 p45 Monoclonal Antibody
Product details
Background:
This gene encodes a member of the F-box protein family which is characterized by an approximately 40 amino acid motif, the F-box. The F-box proteins constitute one of the four subunits of ubiquitin protein ligase complex called SCFs (SKP1-cullin-F-box), which function in phosphorylation-dependent ubiquitination. The F-box proteins are divided into 3 classes: Fbws containing WD-40 domains, Fbls containing leucine-rich repeats, and Fbxs containing either different protein-protein interaction modules or no recognizable motifs. The protein encoded by this gene belongs to the Fbls class; in addition to an F-box, this protein contains 10 tandem leucine-rich repeats. This protein is an essential element of the cyclin A-CDK2 S-phase kinase. It specifically recognizes phosphorylated cyclin-dependent kinase inhibitor 1B (CDKN1B, also referred to as p27 or KIP1) predominantly in S phase and int
Specifications
| Size | 50μL/100μL |
| Target | Skp2 |
| Reactivity | Human |
| Applications | WB, ELISA |
| MW(Calculated) | 48kD |
| MW(Observed) | |
| Host Species | Mouse |
| Isotype | |
| Conjugate/Modification | Unmodified |
| Recommended Dilution Ratio | WB 1:500-1:2000; ELISA 1:10000; Not yet tested in other applications. |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Purification | Affinity purification |
| Storage | -15°C to -25°C/1 year(Do not lower than -25°C) |
| Concentration | |
| Clonality | Monoclonal |
| Clone Number | 12E6 |
| Immunogen | Purified recombinant fragment of Skp2 p45 (aa1-130) expressed in E. Coli. |
| Specificity | Skp2 p45 Monoclonal Antibody detects endogenous levels of Skp2 p45 protein. |
| Gene Name | SKP2 |
| Protein Name | S-phase kinase-associated protein 2 |
| Other Name | SKP2; / FBXL1; / S-phase kinase-associated protein 2; / Cyclin-A/CDK2-associated protein p45; / F-box protein Skp2; / F-box/LRR-repeat protein 1; / p45skp2 |
| Species | Human |
| Gene ID | 6502 |
| Uniprot | Q13309, |
| Species.1 | Mouse |
| Gene ID.1 | |
| Uniprot.1 | Q9Z0Z3 |
| Species.2 | |
| Gene ID.2 | |
| Uniprot.2 | |
| Cellular Localization | Cytoplasm . Nucleus . |
| Tissue Expression | Epithelium,Liver,Placenta,Prostatic carcinoma, |
| Signaling_pathway | Cellular Processes >> Cell growth and death >> Cell cycle;Human Diseases >> Cancer: overview >> Pathways in cancer;Human Diseases >> Cancer: specific types >> Small cell lung cancer;Environmental Information Processing >> Signal transduction >> FoxO signaling pathway;Environmental Information Processing >> Signal transduction >> mTOR signaling pathway;Genetic Information Processing >> Folding, sorting and degradation >> Ubiquitin mediated proteolysis |
| Research Areas | >>FoxO signaling pathway; / >>Cell cycle; / >>Ubiquitin mediated proteolysis; / >>mTOR signaling pathway; / >>Epstein-Barr virus infection; / >>Pathways in cancer; / >>Viral carcinogenesis; / >>Small cell lung cancer |
| Function | Function:Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins involved in cell cycle progression, signal transduction and transcription. Specifically recognizes phosphorylated CDKN1B/p27kip and is involved in regulation of G1/S transition. Degradation of CDKN1B/p27kip also requires CKS1. Recognizes target proteins ORC1L, CDT1, RBL2, MLL, CDK9, RAG2, FOXO1A, UBP43, and probably MYC, TOB1 and TAL1. Degradation of TAL1 also requires STUB1. Recognizes CDKN1A in association with CCNE1 or CCNE2 and CDK2.,pathway:Protein modification; protein ubiquitination.,similarity:Contains 1 F-box domain.,similarity:Contains 8 LRR (leucine-rich) repeats.,subunit:Part of the SCF(SKP2) complex consisting of CUL1, RBX1, SKP1 and SKP2. Interacts directly with CUL1 and SKP1. Interacts with CKS1. Interacts with the cyclin A-CDK2 complex. Interacts with ORC1L, phosphorylated CDT1, phosphorylated RBL2, ELF4, phosphorylated RAG2, FOXO1A, UBP43, MYC, TOB1, TAL1 and MLL., |





